首页 > 市场调查报告书 > 医疗设备

医学影像诊断核子医学

市场调查报告书

商品编码

1471986

Gallium-68 市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按应用程式、最终用户和地理位置

Gallium-68 Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application, End User, and Geography

出版日期: 2024年03月04日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格

简介目录

镓68市场规模预计将从2022年的7.8236亿美元成长到2030年的10.7034亿美元；预计2022年至2030年复合年增长率为4.0%。

Gallium-68 市场的市场驱动因素

先进的放射技术为诊断和核子医学、放射治疗和介入放射学开闢了新的视野。电离辐射在诊断和治疗中的应用使全球数百万患者受益。正子断层扫描 (PET) 是临床环境中常用的核子医学放射学方式，因为它有助于准确检测、定位和表征疾病。根据世界卫生组织 (WHO) 统计，全球每年进行超过 36 亿次放射诊断检查、3,700 万次核医手术和 750 万次放射治疗。根据欧盟委员会的数据，欧洲每年使用放射性药物和影像仪器进行约 1,000 万次核子医学手术，以诊断疾病并提供有针对性的治疗。这些技术也被用于肿瘤学、免疫学、感染研究、胃肠病学、心臟病学、神经病学和精神病学。用于 PET/CT 的新型放射性药物的开发和推出以及不同肿瘤分期方法的准确性不断提高，促进了镓 68 市场的成长。例如，新推出的前列腺成像放射性药物如Ga-68 gozetotide有助于更精确的前列腺癌成像。

镓68市场的限制

放射性药物的半衰期取决于放射性同位素的半衰期和放射化学稳定性以及製剂中放射性核种杂质含量等多种因素。大多数放射性药物製剂含有半衰期很短的放射性同位素。 Gallium-68 必须在製备后 68 分钟内使用。无菌撤回第一剂后多剂量放射性药物製剂的保存期限取决于微生物条件。保质期较短的诊断放射性药物通常在医院放射性药剂科在给患者服用之前製备。镓68的半衰期为68分钟，远低于氟18（109.8分钟）和锝99m（6小时）等其他放射性药物的半衰期。因此，放射性药物的短寿命成为长期程序的障碍，这是限制镓68市场成长的主要因素。

Gallium-68 市场的机会

Gallium-68 已成为治疗诊断领域不可或缺的一部分，该领域将诊断测试与标靶治疗相结合。将镓 68 与镥 177 等治疗性放射性药物结合使用，提供了一个有前途的个人化癌症治疗和管理机会。镓 68 作为诊断工具和治疗剂的双重作用与人们日益重视个人化和精确的癌症照护一致。因此，日益增长的治疗诊断和精准医学预计将为市场成长提供利润丰厚的机会。

Gallium-68 市场：细分市场概述

肿瘤学领域在 2022 年占据最大的 68 镓市场份额，预计在预测期内复合年增长率最高。肿瘤领域的市场细分为前列腺癌、神经内分泌肿瘤等。

按最终用户划分，市场分为医院、诊断和成像中心等。到 2022 年，医院细分市场将占据最大的镓 68 市场份额。

Gallium-68 市场：地理概况

据估计，2022 年至 2030 年亚太地区的复合年增长率最高。印度和中国等亚太国家拥有 68 镓市场的巨大成长潜力。 2022年，北美占据最大的68镓市场。由于混合成像等技术的进步、用于诊断和治疗的新型放射性药物的引入以及基于示踪剂原理的分子成像技术的发展，美国核医学取得了显着的发展。先进的医疗基础设施、前列腺癌发病率和患病率的上升以及主要参与者的产品创新进一步促进了北美 68 镓市场的扩张。根据国际癌症研究机构 (IARC) 的数据，美国的癌症病例数预计将从 2020 年的 228 万例增加到 2040 年的 312 万例。，这有利于镓68市场的进步。

在准备 68 镓市场报告时提到的一些主要一手和二手来源包括世界银行数据、国家医疗服务体系 (NHS)、FDA（食品和药物管理局）、EMA（欧洲药品管理局）和WHO（世界卫生组织）。

欧洲
- 德国
- 法国
- 义大利
- 西班牙
- 英国
- 欧洲其他地区
亚太
- 澳洲
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地区

第 10 章：产业格局

併购
协议、合作、合资企业
新产品发布
扩张和其他策略发展

第 11 章：竞争格局

关键参与者的热图分析
公司定位与专注

第 12 章：镓 68 市场 - 主要公司概况

Novartis AG
ITM Medical Isotopes GmbH
IRE-ELiT SA
Telix Pharmaceuticals (US) Inc
Eckert and Ziegler Radiopharma Gmbh
ARTMS Inc
IBA Radiopharma Solutions
Cardinal Health
Rosatom
Evergreen Theragnostics Inc

第 13 章：附录

简介目录

Product Code: TIPRE00029992

The gallium-68 market size is expected to grow from US$ 782.36 million in 2022 to US$ 1,070.34 million by 2030; it is anticipated to record a CAGR of 4.0% from 2022 to 2030.

Market Drivers of the Gallium-68 Market

Advanced radiation technology has opened new horizons in diagnostic and nuclear medicine, radiotherapy, and interventional radiology. The application of ionizing radiation in diagnoses and treatments benefits millions of patients globally. Positron emission tomography (PET) is a commonly used nuclear medicine radiology modality in clinical settings, as it aids in the accurate detection, localization, and characterization of diseases. According to the World Health Organization (WHO), more than 3,600 million radiology-based diagnostic examinations, 37 million nuclear medicine procedures, and 7.5 million radiotherapy treatments are performed annually worldwide. As per the European Commission, ~10 million nuclear medicine procedures are performed with radiopharmaceuticals and imaging instruments every year in Europe to diagnose diseases and deliver targeted treatments. These techniques are also adopted in oncology, immunology, infection studies, gastroenterology, cardiology, neurology, and psychiatry. The development and introduction of new radiopharmaceuticals for PET/CT and the growing accuracy of different tumor staging methods contribute to the gallium-68 market growth. For instance, newly introduced prostate imaging radiopharmaceuticals such as Ga-68 gozetotide help in more precise prostate cancer imaging.

Restraint of the Gallium-68 Market

The half-life of radiopharmaceuticals depends on the half-life and radiochemical stability of radioisotopes and the radionuclide impurity content in the preparation, among other miscellaneous factors. Most radiopharmaceutical preparations contain radioisotopes with very short half-lives. Gallium-68 must be used within 68 minutes of preparation. The shelf-life of a multidose radiopharmaceutical preparation after aseptic withdrawal of the first dose depends on microbiological conditions. Diagnostic radiopharmaceuticals having short shelf lives are usually prepared in the hospital radiopharmacy departments just before the administration to patients. The half-life of gallium-68 is 68 minutes, which is considerably less than the half-life of other radiopharmaceuticals such as fluorine-18 (109.8 minutes) and technetium-99m (6 hours). Therefore, the short life of radiopharmaceuticals turns out to be a hindrance in long-term procedures, which is a major factor restraining the gallium-68 market growth.

Opportunities in the Gallium-68 Market

Gallium-68 has become integral to the field of theranostics, which combines diagnostic testing with targeted therapy. Using gallium-68 with therapeutic radiopharmaceuticals like lutetium-177 presents a promising personalized cancer treatment and management opportunity. This dual role of gallium-68 as both a diagnostic tool and a therapeutic agent aligns with the increasing emphasis on personalized and precise cancer care. Thus, the increasing theranostics and precision medicine are expected to provide lucrative opportunities for market growth.

Gallium-68 Market: Segmental Overview

The oncology segment held the largest gallium-68 market share in 2022 and is anticipated to register the highest CAGR during the forecast period. The market for the oncology segment is subsegmented into prostate cancer, neuroendocrine tumors, and others.

The market, by end user, is categorized into hospitals, diagnostic and imaging centers, and others. The hospitals segment held the largest gallium-68 market share in 2022. Further, the same segment is anticipated to register the highest CAGR during the forecast period.

Gallium-68 Market: Geographical Overview

Asia Pacific is estimated to register the highest CAGR during 2022-2030. Countries in the Asia Pacific, such as India and China, hold significant potential for the growth of the gallium-68s market. In 2022, North America held the largest gallium-68 market share. Nuclear medicine in the US has grown significantly owing to advancements in technologies such as hybrid imaging, the introduction of novel radiopharmaceuticals for diagnosis and treatment, and the development of molecular imaging techniques based on the tracer principle. Access to advanced healthcare infrastructure, the rising incidence and prevalence of prostate cancer, and product innovations by key players further contribute to the expansion of the gallium-68 market in North America. According to the International Agency for Research on Cancer (IARC), the number of cancer cases in the US is expected to increase from 2.28 million cases in 2020 to 3.12 million cases by 2040. Thus, the increasing cancer cases are expected to boost demand for nuclear imaging, which favors the gallium-68 market progress.

A few of the major primary and secondary sources referred to while preparing the report on the gallium-68 market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization).

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Gallium-68 Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Gallium-68 Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Gallium-68 Market - Global Market Analysis

6.1 Gallium-68 - Global Market Overview
6.2 Gallium-68 - Global Market and Forecast to 2030

7. Gallium-68 Market - Revenue Analysis (USD Million) - By Application, 2020-2030

7.1 Overview
7.2 Oncology
- 7.2.1 Prostate Cancer
- 7.2.2 Neuroendocrine Tumors
- 7.2.3 Others
7.3 Cardiology
7.4 Neurology
7.5 Others

8. Gallium-68 Market - Revenue Analysis (USD Million) - By End-User, 2020-2030

8.1 Overview
8.2 Hospitals
8.3 Diagnostic and Imaging Centers
8.4 Others

9. Gallium-68 Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

9.1 North America
- 9.1.1 North America Gallium-68 Market Overview
- 9.1.2 North America Gallium-68 Market Revenue and Forecasts to 2030
- 9.1.3 North America Gallium-68 Market Revenue and Forecasts and Analysis - By Application
- 9.1.4 North America Gallium-68 Market Revenue and Forecasts and Analysis - By End-User
- 9.1.5 North America Gallium-68 Market Revenue and Forecasts and Analysis - By Countries
  - 9.1.5.1 United States Gallium-68 Market
    - 9.1.5.1.1 United States Gallium-68 Market, by Application
    - 9.1.5.1.2 United States Gallium-68 Market, by End-User
  - 9.1.5.2 Canada Gallium-68 Market
    - 9.1.5.2.1 Canada Gallium-68 Market, by Application
    - 9.1.5.2.2 Canada Gallium-68 Market, by End-User
  - 9.1.5.3 Mexico Gallium-68 Market
    - 9.1.5.3.1 Mexico Gallium-68 Market, by Application
    - 9.1.5.3.2 Mexico Gallium-68 Market, by End-User

Note - Similar analysis would be provided for below mentioned regions/countries

9.2 Europe
- 9.2.1 Germany
- 9.2.2 France
- 9.2.3 Italy
- 9.2.4 Spain
- 9.2.5 United Kingdom
- 9.2.6 Rest of Europe
9.3 Asia-Pacific
- 9.3.1 Australia
- 9.3.2 China
- 9.3.3 India
- 9.3.4 Japan
- 9.3.5 South Korea
- 9.3.6 Rest of Asia-Pacific
9.4 Middle East and Africa
- 9.4.1 South Africa
- 9.4.2 Saudi Arabia
- 9.4.3 U.A.E
- 9.4.4 Rest of Middle East and Africa
9.5 South and Central America
- 9.5.1 Brazil
- 9.5.2 Argentina
- 9.5.3 Rest of South and Central America

10. Industry Landscape

10.1 Mergers and Acquisitions
10.2 Agreements, Collaborations, Joint Ventures
10.3 New Product Launches
10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration

12. Gallium-68 Market - Key Company Profiles

12.1 Novartis AG
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments

Note - Similar information would be provided for below list of companies